CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
表达嵌合抗原受体的 T 细胞治疗多形性胶质母细胞瘤的进展：文献综述与未来方向
英文原题：Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions.
查看英文原题
Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多形性胶质母细胞瘤（GBM）是一种侵袭性癌症，治疗困难，通常需要包括手术、放疗和化疗在内的多模式治疗。表达嵌合抗原受体的（CAR-T）细胞在治疗血液系统恶性肿瘤方面已显示出疗效，并促成了多种FDA批准的疗法。近年来，CAR-T 细胞已被研究用于治疗GBM，并取得了一些有前景的临床前和临床结果。本文献综述的目的是强调常用的靶抗原、临床试验结果、新型修饰以及使CAR-T 细胞更广泛地应用并有效根除GBM所面临挑战的潜在解决方案。
展开英文摘要原文
Glioblastoma multiforme (GBM) is an aggressive cancer that has been difficult to treat and often requires multimodal therapy consisting of surgery, radiotherapy, and chemotherapy. Chimeric antigen receptor-expressing (CAR-T) cells have been efficacious in treating hematological malignancies, resulting in several FDA-approved therapies.
CAR-T cells have been more recently studied for the treatment of GBM, with some promising preclinical and clinical results. The purpose of this literature review is to highlight the commonly targeted antigens, results of clinical trials, novel modifications, and potential solutions for challenges that exist for CAR-T cells to become more widely implemented and effective in eradicating GBM.
论文信息
- 作者
- Goutnik M、Iakovidis A、Still MEH、Moor RSF、Melnick K、Yan S、Abbas M、Huang J
- 单位
- Department of Neurosurgery, College of Medicine, University of Florida, Gainesville, Florida, USA.United States
- 文献类型
- 综述
- 期刊
- Neuro-oncology advances2024 Jan-Dec
- 原文标识
- PubMed 38486856 · DOI 10.1093/noajnl/vdae025
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →